A Study of Real-life Current Standards of Care in Patients With Relapsed and/or Refractory Multiple Myeloma Who Received at Least 3 Prior Lines of Therapy Including Proteasome Inhibitor (PI) Immunomodulatory Drug (IMID) and Cluster of Differentiation 38 (CD38) Monoclonal Antibody Treatment

  • STATUS
    Not Recruiting
  • End date
    Oct 27, 2022
  • participants needed
    230
  • sponsor
    Janssen-Cilag Ltd.
Updated on 2 June 2021
monoclonal antibodies
maintenance therapy
progressive disease
monoclonal protein
proteasome inhibitor
refractory multiple myeloma
immunotherapeutic agent
immunomodulatory imide drug

Summary

The purpose of this study is to assess the safety and clinical response including overall response rate (ORR) of real-life standard-of-care (SOC) treatments under routine clinical practice, over a 24-month period, in patients with relapsed/refractory multiple myeloma (RRMM).

Details
Condition Multiple Myeloma, Lymphoproliferative Disorder, Lymphoproliferative disorders
Treatment No intervention
Clinical Study IdentifierNCT04035226
SponsorJanssen-Cilag Ltd.
Last Modified on2 June 2021

Similar trials to consider

Loading...

Browse trials for

Not finding what you're looking for?

Every year hundreds of thousands of volunteers step forward to participate in research. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.

Sign up as volunteer

user name

Added by • 

 • 

Private

Reply by • Private
Loading...

Lorem ipsum dolor sit amet consectetur, adipisicing elit. Ipsa vel nobis alias. Quae eveniet velit voluptate quo doloribus maxime et dicta in sequi, corporis quod. Ea, dolor eius? Dolore, vel!

  The passcode will expire in None.
Loading...

No annotations made yet

Add a private note
  • abc Select a piece of text from the left.
  • Add notes visible only to you.
  • Send it to people through a passcode protected link.
Add a private note